

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT8030593

|   |                                |                       |
|---|--------------------------------|-----------------------|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT                 |                       |
| <b>NATURE OF CONVEYANCE:</b>  | MERGER                         |                       |
| <b>EFFECTIVE DATE:</b>  | 12/07/2018                     |                       |
| <b>CONVEYING PARTY DATA</b>   |                                |                       |
|   | <b>Name</b>                    | <b>Execution Date</b> |
|   | ATON PHARMA, INC.              | 12/07/2018            |
| <b>RECEIVING PARTY DATA</b>   |                                |                       |
| <b>Name:</b>  | PRINCETON PHARMA HOLDINGS, LLC |                       |
| <b>Street Address:</b>  | 3150 BRUNSWICK PIKE            |                       |
| <b>City:</b>  | LAWRENCEVILLE                  |                       |
| <b>State/Country:</b>   | NEW JERSEY                     |                       |
| <b>Postal Code:</b>   | 08648                          |                       |
| <b>PROPERTY NUMBERS Total: 1</b>  |                                |                       |
|   | <b>Property Type</b>           | <b>Number</b>         |
|   | Application Number:            | 16241558              |
| <b>CORRESPONDENCE DATA</b>  |                                |                       |
| <b>Fax Number:</b>  |                                |                       |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |                                |                       |
| <b>Phone:</b>   | 5852311342                     |                       |
| <b>Email:</b>   | srousell@hselaw.com            |                       |
| <b>Correspondent Name:</b>  | ANDREW J. ANDERSON             |                       |
| <b>Address Line 1:</b>  | 1600 BAUSCH & LOMB PLACE       |                       |
| <b>Address Line 2:</b>  | HARTER SECREST & EMERY LLP     |                       |
| <b>Address Line 4:</b>  | ROCHESTER, NEW YORK 14604-2711 |                       |
| <b>ATTORNEY DOCKET NUMBER:</b>  | 99336.000347                   |                       |
| <b>NAME OF SUBMITTER:</b>   | ANDREW J. ANDERSON             |                       |
| <b>SIGNATURE:</b>   | /Andrew J. Anderson/           |                       |
| <b>DATE SIGNED:</b>   | 06/28/2023                     |                       |
| <b>Total Attachments: 6</b>   |                                |                       |
| source=99336-347_Certificate_of_Merger_Aton_Princeton_Pharma#page1.tif  |                                |                       |
| source=99336-347_Certificate_of_Merger_Aton_Princeton_Pharma#page2.tif  |                                |                       |
| source=99336-347_Certificate_of_Merger_Aton_Princeton_Pharma#page3.tif  |                                |                       |
| source=99336-347_Certificate_of_Merger_Aton_Princeton_Pharma#page4.tif  |                                |                       |

source=99336-347\_Certificate\_of\_Merger\_Aton\_Princeton\_Pharma#page5.tif

source=99336-347\_Certificate\_of\_Merger\_Aton\_Princeton\_Pharma#page6.tif

**PATENT**

**REEL: 064095 FRAME: 0683**

**CERTIFICATE OF OWNERSHIP AND MERGER  
MERGING  
ATON PHARMA, INC.  
WITH AND INTO  
PRINCETON PHARMA HOLDINGS, LLC**

December 7, 2018

Pursuant to Section 18-209 of the Delaware Limited Liability Company Act (the “**DLLCA**”) and Section 267 of the Delaware General Corporation Law (the “**DGCL**”), Princeton Pharma Holdings, LLC, a Delaware limited liability company (the “**Parent**”), does hereby certify to the following information relating to the merger (the “**Merger**”) of Aton Pharma, Inc., a Delaware corporation (the “**Aton**”), with and into the Parent, with the Parent remaining as the surviving company.

FIRST: The Parent owns all of the issued and outstanding shares of each class of capital stock of Aton.


SECOND: In accordance with the limited liability company operating agreement of the Parent and the DLLCA, the sole member of the Parent has, by resolutions duly adopted by written consent on December 7, 2018 and attached hereto as Exhibit A, determined to merge Aton with and into the Parent.

THIRD: The Parent shall be the surviving company of the Merger.

IN WITNESS WHEREOF, the undersigned has executed this Certificate of Ownership and Merger as of the date first written above.

**PRINCETON PHARMA HOLDINGS, LLC**

By: \_\_\_\_\_

  
Name: Jeremy M. Lipshy  
Title: Senior Vice President, Tax

*[Signature Page to Certificate of Ownership and Merger - Princeton Pharma Holdings, LLC]*

**PATENT**  
**REEL: 064095 FRAME: 0685**

**EXHIBIT A**

(See Attached)

**PRINCETON PHARMA HOLDINGS, LLC**

**CONSENT OF SOLE MEMBER**

December 7, 2018

The undersigned, being the sole member (the “**Member**”) of Princeton Pharma Holdings, LLC, a Delaware limited liability company (the “**Company**”), acting pursuant to Section 18-302(d) of the Delaware Limited Liability Company Act (the “**DLLCA**”), hereby adopts, by this written consent, the following resolutions:

WHEREAS, the Company owns all of the issued and outstanding shares of each class of capital stock of Aton Pharma, Inc., a Delaware corporation (“**Aton**”);

WHEREAS, it is deemed advisable and in the best interests of the Company and the Member that the Company merge Aton with and into the Company; and

WHEREAS, the Merger (defined below) is intended to be treated as a reorganization within the meaning of Section 368(a) of the United States Internal Revenue Code of 1986, as amended (the “**Code**”), and this consent, together with the other documents effectuating and approving the Merger, is intended to constitute a “plan of reorganization” within the meaning of Section 368 and related provisions of the Code.

NOW, THEREFORE, IT IS:

RESOLVED, that Aton be merged with and into the Company pursuant to Section 18-209 of the DLLCA and Section 267 of the Delaware General Corporation Law (the “**DGCL**”) (the “**Merger**”), so that the separate existence of Aton shall cease as soon as the Merger shall become effective, and the Company shall continue as the surviving company (the “**Surviving Company**”);

RESOLVED, that the Merger shall become effective upon the filing of the Certificate of Ownership and Merger with the Secretary of State of the State of Delaware (the “**Effective Time**”);

RESOLVED, that, at the Effective Time, by virtue of the Merger and without any action on the part of the holder thereof (a) each share of capital stock of Aton outstanding immediately prior to the Effective Time shall be canceled and no consideration shall be issued in respect thereof and (b) each limited liability company interest in the Company outstanding immediately prior to the Effective Time shall remain unchanged and continue to remain outstanding as a limited liability company interest in the Surviving Company;

RESOLVED, that, until amended in accordance with applicable law, (a) the certificate of formation of the Company in effect at the Effective Time shall be the certificate of formation of the Surviving Company and (b) the limited liability company operating agreement of the Company in effect at the Effective Time shall be the limited liability company operating agreement of the Surviving Company;

RESOLVED, that from and after the Effective Time, until successors are duly elected or appointed and qualified in accordance with applicable law, the officers of the Company at the Effective Time shall be the officers of the Surviving Company;

RESOLVED, that this consent, together with the other documents effectuating and approving the Merger, shall constitute a “plan of reorganization” for purposes of Section 368 and related provisions of the Code with respect to the transactions contemplated hereby;

RESOLVED, that, to the extent contemplated under applicable law, this consent, together with the other documents effectuating and approving the Merger, shall also constitute a “plan of liquidation” within the meaning of Section 332 and related provisions of the Code;

RESOLVED, that any member, officer or officer of any member of the Company (each, an “**Authorized Person**”) be, and each of them hereby is, authorized and empowered, in the name and on behalf of the Company, to take any and all actions, and execute, deliver and file any and all documents, agreements, certificates and other papers, deemed by any such Authorized Person to be necessary or desirable to carry out the purpose and intent of each of the foregoing resolutions (including, without limitation, the execution and delivery of a certificate of ownership and merger and the filing thereof with the Secretary of State of the State of Delaware in accordance with Section 18-209 of the DLLCA and Sections 103 and 267 of the DGCL), the authority therefor to be conclusively evidenced by the taking of such actions or the execution of such documents; and

RESOLVED, that all actions previously taken by the Company and any Authorized Person in connection with any matter referred to in any of the foregoing resolutions are hereby approved, ratified and confirmed in all respects as fully as if such actions had been presented to the Member for its approval prior to such actions being taken.

The actions taken by this consent shall have the same force and effect as if taken at a meeting of the members of the Company, duly called and constituted pursuant to the DLLCA.

*[Remainder of this page intentionally left blank]*

IN WITNESS WHEREOF, the undersigned sole member of the Company has executed this consent as of the date first written above.

**VALEANT PHARMACEUTICALS  
INTERNATIONAL**

By: 

Name: Jeremy M. Lipshy

Title: Senior Vice President, Tax

*[Signature Page to Consent of the Sole Member of Princeton Pharma Holdings, LLC]*